4Filed Aug 12, 8:00 PM ET

Amneal (AMRX) EVP Jason B. Daly Sells 216,613 Shares

$AMRX · Amneal Pharmaceuticals, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Amneal (AMRX) EVP Jason B. Daly Sells 216,613 Shares

What Happened
Jason B. Daly, EVP and Chief Legal Officer of Amneal Pharmaceuticals (AMRX), sold a total of 216,613 shares in two reported transactions. On 2026-08-11 he sold 6,613 shares at a weighted average price of $17.70 for proceeds of $117,050; on 2026-08-12 he sold 210,000 shares at a weighted average price of $17.40 for proceeds of $3,654,000. Total reported proceeds across both sales were approximately $3,771,050. These were sales (not purchases), which are often routine liquidity transactions rather than an indicator of company outlook.

Key Details

  • Transaction dates: 2026-08-11 (6,613 shares) and 2026-08-12 (210,000 shares).
  • Reported weighted-average prices and proceeds: $17.70 → $117,050 (8/11); $17.40 → $3,654,000 (8/12); combined ≈ $3,771,050.
  • Footnotes: Prices are weighted averages from multiple trades. 8/11 trades ranged $17.65–$17.73 (F1); 8/12 trades ranged $17.25–$17.67 (F2). Reporting person will provide per-trade breakdown to Amneal or SEC staff on request.
  • Transaction type: Marked "S" (open market or private sale). No 10b5-1 plan, option exercise, gift, or tax-withholding note was indicated in the provided filing.
  • Shares owned after transaction: Not disclosed in the information supplied here.
  • Timeliness: Form 4 was filed on 2026-08-13 for trades on 8/11–8/12—filed within the typical two-business-day reporting window.

Context
Sales by executives can reflect routine portfolio or liquidity needs and do not by themselves indicate a change in company fundamentals. This filing documents cash sales (not option exercises or awards). If you want per-trade pricing or ownership-after-sale details, those can be requested from Amneal or obtained from the full SEC Form 4 filing (Accession: 0001628280-26-056754).